RHUMBLINE ADVISERS

Position in GMAB — Genmab A/S

CIK 1115418 BOSTON, MA

Position in GMAB

as of Mar 31, 2026 · filed May 12, 2026 Compact

Position Value

$1,061,448

-$80,061 QoQ

Shares Held

39,562

+6.7% QoQ

Ownership

0.006%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2020

13 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

RHUMBLINE ADVISERS holds $1,237,848,251 across 287 Biotechnology names. GMAB ranks #115 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	423,140	$188,948,935
2	REGN	Regeneron Pharmaceuticals, Inc.	157,781	$121,907,911
3	INCY	Incyte Corp	693,665	$65,287,749
4	ALNY	Alnylam Pharmaceuticals, Inc.	195,277	$64,611,300
5	INSM	INSMED Inc	272,615	$44,578,004
6	JAZZ	Jazz Pharmaceuticals plc	164,542	$31,106,665
7	EXEL	Exelixis, Inc.	723,931	$31,049,400
8	ROIV	Roivant Sciences Ltd.	1,113,266	$30,837,468

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,061,448	39,562	+6.7%	Shares	Sole	2026-05-12
2025-12-31	$1,141,509	37,062	+131.4%	Shares	Sole	2026-02-13
2025-09-30	$491,149	16,014	-6.9%	Shares	Sole	2025-11-06
2025-06-30	$355,496	17,207	+1.5%	Shares	Sole	2025-08-12
2025-03-31	$331,998	16,956	+3.2%	Shares	Sole	2025-05-29
2024-12-31	$342,768	16,424	-12.9%	Shares	Sole	2025-05-29
2024-09-30	$459,660	18,854	+0.9%	Shares	Sole	2024-11-12
2024-06-30	$469,780	18,694	+7.1%	Shares	Sole	2024-08-01
2024-03-31	$522,168	17,458	+10.1%	Shares	Sole	2024-05-09
2023-12-31	$504,855	15,856	-2.4%	Shares	Sole	2024-02-08
2023-09-30	$572,820	16,241	+2.0%	Shares	Sole	2023-11-09
2023-06-30	$605,499	15,930	+180.6%	Shares	Sole	2023-08-08
2020-12-31	$230,826	5,677	—	Shares	Sole	2021-02-10
No filing history on record for this holder in this stock.